A Randomised Clinical Trial of a Theory-Based Fentanyl Overdose Education and Fentanyl Test Strip Distribution Intervention to Reduce Rates of Opioid Overdose: Study Protocol for A Randomized Controlled Trial

Brendan Jacka  
Brown University School of Public Health  
https://orcid.org/0000-0002-5910-853X

Jacqueline E Goldman  
Brown University School of Public Health

Jesse Yedinak  
Brown University School of Public Health

Edward Bernstein  
Boston University

Scott E Hadland  
Boston Medical Center

Jane A Buxton  
BC Centre for Disease Control

Susan G Sherman  
Johns Hopkins University

Katie Biello  
Brown University School of Public Health

Brandon DL Marshall (brandon_marshall@brown.edu)  
Brown University School of Public Health  
https://orcid.org/0000-0002-0134-7052

Study protocol

Keywords: Opioid overdose, Behavioural intervention, Motivational interviewing, Fentanyl test strip, Illicitly manufactured fentanyl, Overdose prevention, Information-motivation-behavioural model

DOI: https://doi.org/10.21203/rs.3.rs-45321/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** Opioid overdose deaths involving synthetic opioids, particularly illicitly manufactured fentanyl, remain a substantial public health concern in North America. Responses to overdose events (e.g. administration of naloxone and rescue breathing) are effective at reducing mortality; however, more interventions are needed to prevent overdoses involving illicitly manufactured fentanyl. This study protocol aims to evaluate the effectiveness of a behaviour change intervention that incorporates individual counseling, practical training in fentanyl test strip use, and distribution of fentanyl test strips for take home use among people who use drugs.

**Methods:** Residents of Rhode Island aged 18–65 years who report recent substance use (including prescription pills obtained from the street; heroin, powder cocaine, crack cocaine, methamphetamine; or any drug by injection) (n=500) will be recruited through advertisements and targeted street-based outreach into a two-arm randomised clinical trial with 12 months of post-randomisation follow-up. Eligible participants will be randomised (1:1) to receive either the RAPIDS intervention (i.e. fentanyl-specific overdose education, behaviour change motivational interviewing (MI) sessions focused on using fentanyl test strips to reduce overdose risk, fentanyl test strip training, and distribution of fentanyl test strips for personal use), or standard overdose education as control. Participants will attend MI booster sessions (intervention) or attention-matched control sessions at 1, 2, and 3 months post-randomisation. All participants will be offered naloxone at enrolment. The primary outcome is a composite measure of self-reported overdose in the previous month at six- and/or 12-month follow-up visit. Secondary outcome measures include administratively linked data regarding fatal (post-mortem investigation) and non-fatal (hospitalisation or emergency medical service utilisation) overdoses.

**Discussion:** If the RAPIDS intervention is found to be effective, its brief MI and fentanyl test strip training components could be easily incorporated into existing community-based overdose prevention programming to help reduce the rates of fentanyl-related opioid overdose.

**Trial Registration:** clinicaltrials.gov: NCT04372238; 01 May 2020

Background

Opioid overdose morbidity and mortality remain substantial public health threats in North America, particularly in the era of highly potent novel synthetic opioid agents (1). Mortality related to opioid overdose is also a global concern, with the greatest impact in North America, Europe, and Australasia (2). Contamination of the street drug supply with illicitly manufactured fentanyl (IMF) and its analogs has precipitated dramatic increases in mortality in the United States and Canada, representing a period of substantially increased risk for people who use drugs (PWUD) (3). As IMF contamination expands to illicit stimulant and other non-opioid substances, the potential number of opioid-naïve individuals at risk of opioid overdose has also increased (4, 5).
Overdose prevention efforts include medications for opioid use disorder, overdose education and naloxone distribution (OEND) programs, overdose prevention sites and supervised consumption services, and drug testing services (6–8). Studies show that PWUD modify or adapt their drug use behaviour in light of increased overdose risk associated with synthetic opioid contamination, including using smaller doses to test drug strength, maintaining consistent drug supply, consuming drugs with others present, reducing drug consumption, and having naloxone present (9, 10). However, as contamination of the drug supply with IMF becomes more prevalent, novel tools to prevent and respond to opioid overdose events are urgently needed.

In recent years, analytic tests to detect fentanyl contamination have received substantial attention (11). Traditional forensic testing technologies such as mass spectrometry can identify fentanyl and other synthetic analogs in drug samples, but are expensive and require specialised training and reagents (12). Rapid and simple point of care tests have been proposed as an alternative tool for increasing access to fentanyl testing services in highly marginalised communities, and in drug-using populations without access to supervised consumption facilities, as is currently the case in the United States. Paper-based immunoassays (e.g. Rapid Response™ fentanyl test strip, BTNX Corporation, Canada) provide similar sensitivity and specificity compared to portable mass spectrometers, with low technical requirements and results within five minutes (13). People who use drugs report interest in knowing if fentanyl is in their drugs prior to use, with high willingness and acceptability to use fentanyl test strips in the future (14, 15). Furthermore, early studies have shown that positive fentanyl test strip outcomes results in positive drug use behaviour change, and participants report a desire to perform testing prior to drug use and in private locations (16, 17). Novel drug testing modalities that increase harm reduction self-efficacy will be paramount in assisting and supporting PWUD at risk of fentanyl overdose.

The study protocol described herein aims to test the efficacy of a novel behaviour change intervention that incorporates fentanyl testing strips with a theory-driven opioid overdose risk reduction component. Guided by two health behaviour frameworks, we hypothesise that combining motivational interviewing counseling techniques to increase willingness and self-efficacy to use fentanyl test strips with fentanyl test strip training and teach back will result in enhanced overdose risk reduction practice, compared to participants receiving standard overdose education and naloxone training. We hypothesise that exposure to the Rhode Island Prescription and Illicit Drug Study (RAPIDS) intervention will reduce rates of fatal and non-fatal overdose. Mediation analysis will assess the differential uptake of behaviour changes in participants receiving the intervention.

**Methods/design**

**Participants, interventions, and outcomes**

**Study setting**

The RAPIDS Clinical Trial will be undertaken in the state of Rhode Island, a population of 1 million with sustained high rates of overdose mortality associated with any opioids (25.9 per 100,000 people in 2017).
Death involving synthetic opioids other than methadone (mostly fentanyl) increased substantially both nationally and within Rhode Island between 2013 and 2018, accounting for eight in 10 fatal overdose events in the state (1). Opioid overdose deaths in Rhode Island involving both fentanyl and other opioids appear geographically constrained, with hot spots of overdose deaths observed in a few urban centers in the state (18).

**Eligibility criteria**

Inclusion criteria for the study are: (a) 18 to 65 years of age; (b) reside in Rhode Island; (c) able to complete interviews in English; (d) able to provide informed consent; and (e) report past 30 day use of heroin, illicit stimulants (e.g., powder cocaine, crack cocaine, methamphetamine), counterfeit prescription pills, or any drug by injection, regardless of treatment status. Exclusion criteria are: (a) refusal of consent to participate, (b) unable to provide informed consent due to altered mental status; (c) unable to adequately hear and/or comprehend the consent process; (d) use of prescription medications exclusively obtained from a physician or diverted from someone else's prescription.

**Patient and public involvement**

No patient involved.

**Interventions**

All participants will be randomised to receive either the RAPIDS intervention or a control condition (usual care). An overview of the study design is shown in Figure 1; intervention components are described below.

**Usual care**

Participants in the control arm will receive standardised OEND training, as currently occurs in Rhode Island for people who are at risk for an overdose (19). Based on common components of many community-based overdose prevention interventions, the OEND training includes information on overdose recognition and response, including an educational video on recognising overdose symptoms, and basic overdose response (e.g., performing rescue breaths; administering naloxone; and calling for medical assistance). All participants will be offered a naloxone kit and education material at baseline, and referrals to community locations for no-cost or low-cost naloxone access will be provided at subsequent study visits.

**Motivational interviewing-based brief intervention (RAPIDS intervention)**

Participants in the RAPIDS intervention arm will receive: (1) a brief (15-minute) overdose education and behaviour change counseling session using motivational interviewing, (2) fentanyl test-strip training, roleplay, and teach back, and (3) training videos at the baseline study visit (Figure 1). The intervention is informed by the information-motivation-behavioural skills (IMB) model of behaviour change, which hypothesises that if a person possesses the information, motivation, and behavioural skills to act, there is
an increased likelihood that they will fulfill and maintain the desired behaviours (20). The IMB model has been studied extensively and has empirical support as a framework for understanding both drug and sexual risk behaviours (21–23). Participants will receive ten Rapid Response™ fentanyl test strips for personal use at the end of the session (detection cut-off: 20 ng/ml) (13). Motivational interviewing “booster” sessions will occur at 1, 2, and 3 months post-randomisation, with additional test strips provided during the booster session on an as needed basis. The goals of this intervention are to provide participants with: (1) information about the risks of IMF exposure and how to reduce their risk of overdose, including naloxone training; (2) motivational interviewing to assess participants’ willingness and enhance self-efficacy for engaging in overdose risk reduction behaviours; (3) an instructional video and hands-on training to increase behavioural skills in fentanyl rapid test strip use and interpretation, and opportunities to practice using the test strips; and (4) provision of a supply of test strips for personal use.

A conceptual framework outlining intervention components (informed by the IMB model) is shown in Figure 2. Implementation of the intervention will be undertaken by research staff with a history of working in community settings to enable future scalability in resource constrained settings such as needle-syringe programs, emergency departments and health clinics (24–26).

During the brief intervention (approximately 10–15 minutes duration), interventionists will explore the participants’ familiarity with basic overdose recognition and response. Interventionists will discuss characteristics of fentanyl overdose and appropriate response with participants (e.g. rapidity of fentanyl overdose; naloxone as opioid overdose reversal) before checking with participants for understanding of participants and assessment of response. As part of fentanyl test strip training, participants will review the control arm educational video on overdose recognition and response, followed by an instructional video on the use and interpretation of fentanyl test strips. The fentanyl test strip training also includes practice test-strip use and role-play risk reduction behaviour given a positive or negative test-strip result. Motivational interviewing processes that incorporate engaging, focusing, evoking and planning (27) with participants will guide the direction of subsequent conversations. Using the core skills of motivational interviewing (i.e., open-ended questions, offering affirmations, providing reflections, and summarising) (28), participants and interventionists will explore the participants’ responses to the information component of the intervention. Current risk reduction behaviours endorsed by participants will be affirmed by interventionists, and possible ambivalence about reducing overdose risk will be reflected upon. Taken together, these elements will provide a foundation for the interventionist to elicit change talk from a participant as they increase motivation, strengthen self-efficacy, and plan overdose risk reduction behaviours.

In light of the high potency of fentanyl and difficulty differentiating IMF from heroin and many illicit stimulants (11), the behavioural skills building component of the intervention will focus on overdose risk reduction behaviours considered most effective in the era of fentanyl (9,10). Interventionists will discuss with participants to build skills related to: 1) use of drugs with someone else present who could intervene and take action in the event of an overdose; 2) obtaining naloxone and having someone present to administer if necessary; 3) calling 911 immediately if an overdose occurs; and 4) using fentanyl test strips prior to drug consumption.
Outcomes

The primary outcome will be a composite measure of self-reported overdose (defined as a “negative reaction from using too much drugs”, as operationalised previously (29,30)) in the previous month at the six- and/or 12-month follow-up visit. This sensitive definition is especially prudent in the era of IMF, where atypical presentations of opioid overdose may include chest wall rigidity, nausea, and vomiting (31). Self-reported overdose (compared to administrative data linkage) was selected as the primary outcome measure since a minority of participants in a pilot study reported attending a hospital at their last overdose (32). Furthermore, one of our target behaviours of the intervention includes calling 911 and seeking immediate medical attention if an overdose occurs, possibly leading to an increased rate of presentation at emergency departments for overdose events in the intervention arm. Nonetheless, exploratory analysis will utilise deterministic linkage of administrative health data systems in Rhode Island to identify fatal (through medical examiner reports) and non-fatal (through hospitalisation or emergency medical service utilisation) overdose events among participants.

Participant timeline

The trial consists of a 16-week behavioural intervention phase with a 36-week follow-up phase. The total trial period for participants will be 12 months. As shown in Table 1, measurements will be undertaken at six time points in each arm: at baseline, three times during the 12-week intervention program, and at six and 12-month follow-up visits.

Sample size

Sample size/power calculations are based on findings from our pilot intervention study (14). In this study, 37% of participants reported a lifetime history of overdose, and 10% reported a suspected fentanyl-related overdose in the past six months. Therefore, for the present study, we assumed that 20% of participants in the control arm will experience an overdose during the 12-month follow-up period. We conservatively assume an 80% retention rate in the trial, below the 90% retention rate observed in the pilot study. Given these assumptions, with a sample size of 500 participants we have >80% power to detect a 50% reduction in overdoses (i.e., the primary endpoint described above).

Recruitment and retention

As in our pilot intervention study, we will employ a combination of field-based recruitment techniques, Internet-based advertising, and state-wide public transport advertisement to recruit potential study participants. We will employ participant retention strategies that are effective at engaging PWUD, including dedicated study phones; comprehensive participant contact information tracking database; regular outreach in areas that participants are known to frequent; study visit honoraria (Brown University IRB-approved: $35 for baseline visit, $25 per follow-up visit); providing free parking to participants; and routinely searching the public Rhode Island Department of Corrections database to determine participant incarceration (considered lost to follow-up if incarcerated for greater than 90 days). For each visit, contact
will be limited to a maximum of 10 attempts, after which participants will be considered lost to follow up. If participants initiate contact after this, follow-up will continue according to the study schedule and contact attempts count reset.

**Assignment of interventions**

**Allocation and Blinding**

Eligible and consenting participants will be randomly assigned to either control or intervention arm using a simple 1:1 allocation using a permuted block randomisation schedule, operationalised using the Randomization Module in REDCap™. Randomisation will be assigned during the baseline visit following informed consent and completion of a baseline assessment (see below). Intervention allocations will be accessible in REDCap™ by authorised users only, such as the biostatistician, and revealed to interventionists only through REDCap™ by prompts during the baseline and follow-up visits.

**Data collection, management, and analysis**

**Data collection methods**

**Training for data collection staff**

All staff will receive training for human subjects research. Additionally, staff will receive eight hours of relevant education (e.g. harm reduction, naloxone administration, overdose recognition and response, and stigma related to drug use) and 16 hours of didactic and hands-on training in motivational interviewing processes and skills. The motivational interviewing component will be audio recorded and a subset reviewed for fidelity of implementation as an ongoing practice \(^{33}\). Prior to provision of the intervention, all interventionists will be trained in MI by a certified trainer, with random fidelity audits throughout the study period. Interventionists will undertake additional training where initial or audit assessments are below the 100% and 85% benchmarks, respectively.

**Instruments and instrument-related procedures for data collection**

Participant sociodemographics, substance use history, fentanyl knowledge, self-reported overdose and fentanyl exposure, and health service engagement will be captured in a structured biobehavioural questionnaire (Table 1). Standardised instruments will assess mental health (e.g. Generalised Anxiety Disorder 7-item scale, Center for Epidemiologic Studies Depression Scale, CDC Health-Related Quality of Life scale, and Addiction Severity-Index Lite) and substance use treatment (Subjective Opioid Withdrawal Scale; Opiate Dosage Adequacy Scale) outcomes. Urine specimens will be collected and tested for the presence of 12 substances using rapid qualitative test strips (Rapid Response™ Multi-Drug One Step Cup II, BTNX Corporation, ON Canada): amphetamine (AMP-1S2-100; detection cut-off: 1000 ng/ml); benzdiazepine (BZO-1S3-100; detection cut-off: 300 ng/ml); buprenorphine (BUP-1S5-100; detection cut-off: 10 ng/ml); cocaine (COC-1S3-100; detection cut-off: 300 ng/ml); ethyl glucuronide (ETG-1S9-100; detection cut-off: 500 ng/ml); methadone (MTD-1S3-100; detection cut-off: 300 ng/ml); fentanyl (FYL-
1S48-100; detection cut-off: 20 ng/ml); marijuana (THC-1S13-100; detection cut-off: 50 ng/ml); 3,4-methylenedioxyamphetamine (MDM-1S-100; detection cut-off: 500 ng/ml); methamphetamine (MET-1S2-100; detection cut-off: 1000 ng/ml); morphine (MOP-1S3-100; detection cut-off: 300 ng/ml); oxycodone (OXY-1S27-100; detection cut-off: 100 ng/ml); and urine adulteration (URA-1S65).

Data management

Data management guidelines and procedures

The primary source of data will be survey responses, captured using REDCap™ software on laptops and tablet devices for direct, secure, and remote data entry. Probabilistic linkage of administrative datasets will provide an additional source of information regarding opioid overdose events for exploratory analyses. Ongoing surveillance efforts by the Rhode Island Department of Health captures data on all fatal overdose events occurring in the state through the Rhode Island Office of State Medical Examiners, and hospitalisation and emergency medical service utilisation related to suspected nonfatal opioid overdose, as described above (34). Data will be transferred from the Rhode Island Department of Health to Brown University School of Public Health using Health Insurance Portability and Accountability Act-compliant secure file transfer protocols.

Statistical methods

Primary outcome

Using the intention-to-treat procedure, we will determine the efficacy of the intervention by comparing self-reported rates of overdose among those assigned to the intervention arm (RAPIDS intervention) versus the control arm (usual care). A chi-square test of a two-by-two table (statistically significant at p<0.05, two sided) will compare exposure to the intervention and the composite measure of self-reported overdose (defined as a “negative reaction from using too much drugs”) in the previous month at the six- and/or 12-month follow-up visit.

Sensitivity analysis of primary outcome

We will repeat our analysis of the primary outcome using: (1) pooled logistic regression to determine the independent effect of the intervention on self-reported overdose at either or both follow-up visits, adjusting for known or anticipated prognostic variables measured at baseline (e.g., injection drug use, history of overdose); (2) generalised linear mixed effects models (GLMM) with a logit link function to examine differences in self-reported overdose rates at six and 12-month visits; (3) a per-protocol sub-analysis to determine the effect of the intervention on self-reported overdoses among those who used the fentanyl test strips compared to those who did not.

Secondary outcome
Using administrative-linked data of fatal and nonfatal overdose events, Kaplan-Meier estimators and Cox proportional hazards models will be used to determine the hazard of overdose events in the intervention and control groups. Right censoring for time-to-event analyses will occur at time of first identified overdose, estimated date of loss to follow-up, non-opioid overdose related mortality, or end of study.

**Missing data**

At the completion of the study, patterns of outcome and covariate data missingness will be explored to determine the appropriate assumptions required for each affected variable. Using chained equations, the model will specify the conditional models for the missing outcome and covariates as missing completely at random (MCAR), missing at random (MAR), or missing not at random (MNAR). In the case of MNAR, we will specify a subset of the observations to derive the imputation model and may adjust imputed values by using specified shift and scale parameters for a set of selected observations in sensitivity analysis with a tipping-point approach. Finally, models with complete case, available data, and fully imputed data will be compared based on their coefficients, standard errors (SE), and p-value for the covariates included in the model.

**Monitoring**

**Data monitoring**

This study includes an independent Data and Safety Monitoring Board (DSMB) and a Data and Safety Monitoring Plan (DSMP). Further details on the DSMB charter are available on request. The DSMB will meet on a monthly basis for the first six months with the PI, Project Director, Biostatistician, and Study Coordinator to review the DSMP and protocol adherence. Thereafter, the DSMB will determine the schedule for future review meetings. The DSMB will also review any adverse or severe adverse events as outlined in the DSMP. Adverse events (including severe adverse events) will be captured using REDCap™ software during routine participant assessment and spontaneously as required, and reported to relevant parties as necessary.

Interim analyses will be performed when approximately one-third of participants are recruited to assess potential harms, and when approximately two-thirds of participants are recruited to assess efficacy. Using the alpha spending rule (35), p-values will be constructed to maintain the overall study power of 0.05, two-sided, assessing the proportion of expected events (i.e., self-reported non-fatal overdose) in each arm. If the test statistic exceeds the boundary, then the study could be considered for early termination due to emerging differences between the two arms. The study may be stopped due to: 1) evidence of harm based on adverse and severe adverse event reporting and other safety data; 2) early evidence of efficacy from the second planned interim analysis; and 3) if any investigator judges it necessary for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, or good clinical practice. We do not propose that the trial be stopped for futility, as additional information collected at the 12-month follow-up may be useful for public health program planning and practice.
Auditing

The Principal Investigator is ultimately responsible for data safety and monitoring of the study. This process will be monitored on a weekly basis by his team, including the Project Director, Biostatistician, Study Coordinator, and Data Manager, with quarterly updates to the entire team of Co-Investigators. The project team will be responsible for ensuring that all policies and processes outlined in the Data Use Agreement (with Rhode Island Department of Health) are followed accordingly, and that data are transferred and shared on the agreed-upon timeline.

Ethics and dissemination

Research ethics approval

Ethical approval for this study has been obtained from the Brown University Institutional Review Board (ref: 1904002388) and other relevant Institutional Review Boards. Any modifications to the trial protocol (e.g. eligibility, potential benefit or harms, study objectives or design, study procedures) will be subject to approval by Brown University Institutional Review Board and reported to relevant parties as necessary. Administrative amendments resulting in minor changes will be subject to approval by the Brown University Human Research Protection Program.

Consent

Consent will be obtained at the start of pre-screening (verbal or written) for eligibility, and e-signed informed consent at the start of the baseline visit for eligible participants. Participants will be offered a copy of the e-signed informed consent form via email. All participants will be given detailed explanations of their rights as human subjects, including the purpose of the study, length of time for the interview process, study requirements, and risks and benefits of the interventions. At each in-person visit, research personnel will complete a brief verbal assessment using the “Alert & Oriented X4” procedure, where the participants’ awareness of person, time, place and situation is assessed. Furthermore, all research personnel are trained to recognise and respond to an overdose, including calling for medical assistance, administering naloxone, and performing rescue breaths. On-call clinicians and local behavioural health services are available in the event of an emergency.

Confidentiality

All trial-related information will be securely stored at the study site, either in locked filing cabinets in secured areas (paper documents) or in secure Windows-based servers using two-factor authentication (electronic records).

Dissemination policy

This study has been registered on www.ClinicalTrials.gov and all summaries of the results will be published on ClinicalTrials.gov by the Principal Investigator as soon as they become available. Trial
results will be shared in peer-reviewed journals and presented at relevant local, regional, and national scientific meetings, conferences and invited lectureships in a timely fashion. Publication authorship will follow the International Committee of Medical Journal Editors guidelines. All final peer-reviewed manuscripts from the trial will be submitted to PubMed Central digital archive.

Discussion

To date, no randomised clinical trials have examined the efficacy of rapid fentanyl test strips in combination with behaviour change intervention for the prevention of opioid overdose events. Our pilot study of young people at risk of fentanyl exposure demonstrated high willingness to use fentanyl test strips as a harm reduction tool, and the feasibility of a brief training module for non-expert use (14, 16). Furthermore, positive test strip results were associated with drug risk behaviour changes (16). The current randomised clinical trial aims to demonstrate the application of theory-driven motivational interviewing sessions that improve participant self-efficacy in drug risk behaviour reduction alongside fentanyl test strip distribution and brief training in their use.

The results from this randomised clinical trial will need to be considered in light of some limitations. Firstly, participants are being drawn from an unknown sample frame and may not be representative of the greater population of PWUD in Rhode Island or other geographic locations. However, our participant recruitment and retention plan is informed by pilot studies of PWUD in Rhode Island, and will consist of numerous and diverse strategies for participant engagement (36). Secondly, evaluating the effectiveness of a behaviour change and fentanyl test strip intervention versus standard overdose education and naloxone distribution is complicated by the subjective nature of overdose events. Our measure of self-reported overdose captures participants’ perceived negative reactions of using drugs, in line with the literature (29, 30). In addition, we will collect symptomatology of overdose events to better describe the severity of nonfatal overdose events experienced by participants. To address issues with subjective measures of exposure to fentanyl, we have incorporated urine drug testing—for 12 drugs including fentanyl—in the protocol and a three-day recall period for exposure to substances. Finally, loss to follow-up is a key issue for studies of PWUD, compounded by the illicit nature of substance use. We will implement comprehensive participant retention strategies, including text message and email reminders, participant honoraria and subsidised parking, targeted canvassing in spaces where PWUD are known to frequent. To address potential bias related to loss to follow up, administrative data linkage—capturing fatal overdose events reported by the medical examiner, and nonfatal overdose events attended to by emergency medical services or presented at emergency departments—will be utilised in exploratory analyses.

This randomised clinical trial serves as the first such work to evaluate the efficacy of novel drug testing technology combined with a behavioural change component. If found to be effective, the RAPIDS intervention will provide the basis for an affordable program that can be feasibly implemented by harm reduction services for the prevention of opioid overdoses around the world. In light of IMF contamination
of non-opioid substances, novel interventions are necessary to protect the health of people who use drugs.

**Trial Status**

Protocol version number and date: version 1.2; March 19 2020

Expected date recruitment begins: August 1 2020

Approximate date when recruitment will be completed: August 31 2022

**Declarations**

**Ethics approval and consent to participate**

Ethical approval for this study has been obtained from the Brown University Institutional Review Board (ref: 1904002388) and other relevant Institutional Review Boards. Written, informed consent to participate will be obtained from all participants.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The principal investigator (PI) will oversee management of the final trial dataset with the Biostatistician and Data Manager. The PI will determine access to the final trial dataset in instances of formal requests for substudy analyses from co-investigators or collaborators.

**Competing interests**

The authors declare that they have no competing interests.

**Funding:**

This work was supported by the National Institute on Drug Abuse grant number R01DA047975. The funders had no role in the study analysis, decision to publish, or preparation of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Authors’ contributions**

BPJ led the manuscript preparation. The research was conceived by BDLM and JLY. All authors provided feedback on drafts of the study protocol and manuscript. BPJ, JEG, JLY, EB, SEH, JAB, SGS, KB, and BDLM read and approved the final manuscript.
Acknowledgements

We would like to thank our colleagues Drs. Traci Green, Thomas Kerr, Josiah Rich, and Evan Wood for their contribution to the development and funding of the RAPIDS Clinical Trial.

References

1. Wilson N, Kariisa M, Seth P, Smith H 4th, Davis NL. Drug and Opioid-Involved Overdose Deaths - United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020 Mar;20(11):290–7. 69(11):290–7.
2. Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019 Oct;26(10208):1560–79. 394(10208):1560–79.
3. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy [Internet]. 2019 Feb 1; Available from: http://dx.doi.org/10.1016/j.drugpo.2019.01.010.
4. LaRue L, Twillman RK, Dawson E, Whitley P, Frasco MA, Huskey A, et al. Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine. JAMA Netw Open. 2019 Apr 5;2(4):e192851.
5. Gladden RM, O’Donnell J, Mattson CL, Seth P. Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine – 25 States, July-December 2017 to January-June 2018. MMWR Morb Mortal Wkly Rep. 2019 Aug;30(34):737–44. 68(34):737–44.
6. Bardwell G, Kerr T. Drug checking: a potential solution to the opioid overdose epidemic? Subst Abuse Treat Prev Policy. 2018 May 25;13(1):20.
7. Wallace B, Pagan F, Pauly BB. The implementation of overdose prevention sites as a novel and nimble response during an illegal drug overdose public health emergency. Int J Drug Policy. 2019 Apr;66:64–72.
8. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018 Aug 7;169(3):137–45.
9. McKnight C, Des Jarlais DC. Being “hooked up” during a sharp increase in the availability of illicitly manufactured fentanyl: Adaptations of drug using practices among people who use drugs (PWUD) in New York City. International Journal of Drug Policy. 2018 Oct 1;60:82–8.
10. Mars SG, Ondocsin J, Ciccarone D. Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm Reduct J. 2018 May 16;15(1):26.
11. McGowan CR, Harris M, Platt L, Hope V, Rhodes T. Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it? Int J Drug Policy. 2018 Aug;58:31–6.
12. Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J. 2017 Jul 31;14(1):52.

13. Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020 Jan;14:77:102661.

14. Krieger MS, Yedinak JL, Buxton JA, Lysyshyn M, Bernstein E, Rich JD, et al. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct J. 2018 Feb 8;15(1):7.

15. Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. Int J Drug Policy. 2019 Jun;68:46–53.

16. Goldman JE, Waye KM, Periera KA, Krieger MS, Yedinak JL, Marshall BDL. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Harm Reduct J. 2019 Jan 8;16(1):3.

17. Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019 Jan;63:122–8.

18. Marshall BDL, Krieger MS, Yedinak JL, Ogera P, Banerjee P, Alexander-Scott NE, et al. Epidemiology of fentanyl-involved drug overdose deaths: A geospatial retrospective study in Rhode Island, USA. Int J Drug Policy. 2017 Aug;46:130–5.

19. Yokell MA, Green TC, Bowman S, McKenzie M, Rich JD. Opioid overdose prevention and naloxone distribution in Rhode Island. Med Health R I. 2011 Aug;94(8):240–2.

20. Fisher WA, Fisher JD, Harman J. The information-motivation-behavioral skills model: A general social psychological approach to understanding and promoting health behavior. Social psychological foundations of health illness. 2003;583:82–106.

21. Brown W 3rd, Carballo-Diéguez A, John RM, Schnall R. Information. Motivation, and Behavioral Skills of High-risk Young Adults to Use the HIV Self-Test. AIDS and behavior. 20(9):2000–9.

22. Phillips KT, Altman JK, Corsi KF, Stein MD. Development of a risk reduction intervention to reduce bacterial and viral infections for injection drug users. Subst Use Misuse. 2013 Jan;48(1–2):54–64.

23. Fisher CM. Adapting the information-motivation-behavioral skills model: predicting HIV-related sexual risk among sexual minority youth. Health Educ Behav. 2012 Jun;39(3):290–302.

24. Stein MD, Charuvastra A, Maksad J, Anderson BJ. A randomized trial of a brief alcohol intervention for needle exchangers (BRAINE). Addiction. 2002 Jun;97(6):691–700.

25. Fernandez WG, Mitchell PM, Jamanka AS, Winter MR, Bullock H, Donovan J, et al. Brief motivational intervention to increase self-reported safety belt use among emergency department patients. Acad Emerg Med. 2008 May;15(5):419–25.

26. Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend. 2005 Jan 7;77(1):49–59.
27. Miller WR, Rollnick S. Motivational Interviewing: Third Edition: Helping People Change. Guilford Press; 2012.

28. Miller WR, Moyers TB. Eight Stages in Learning Motivational Interviewing. Journal of Teaching in the Addictions. 2006 Jan 1;5(1):3–17.

29. Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016 May;1:162:51–5.

30. Escudero DJ, Marshall BDL, Kerr T, Hayashi K, Feng C, Guillemi SA, et al. No association between HIV status and risk of non-fatal overdose among people who inject drugs in Vancouver, Canada. Addict Behav. 2016 Sep;60:8–12.

31. Suzuki J, El-Haddad S. A review: Fentanyl and non-pharmaceutical fentanyl. Drug Alcohol Depend. 2017 Feb;1:171:107–16.

32. Evans TI, Hadland SE, Clark MA, Green TC, Marshall BDL. Factors associated with knowledge of a Good Samaritan Law among young adults who use prescription opioids non-medically. Harm Reduct J. 2016 Jul 26;13(1):24.

33. Jelsma JGM, Mertens V-C, Forsberg L, Forsberg L. How to Measure Motivational Interviewing Fidelity in Randomized Controlled Trials: Practical Recommendations. Contemp Clin Trials. 2015 Jul;43:93–9.

34. Lasher L, Rhodes J, Viner-Brown S Identification and Description of Non-Fatal Opioid Overdoses using Rhode Island EMS Data, 2016–2018. R I Med J. 2019 Mar 1;102(2):41–5.

35. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13(13–14):1341–52. discussion 1353–6.

36. Marshall BDL, Green TC, Elston B, Yedinak JL, Hadland SE, Clark MA. The Effectiveness of Internet- and Field-Based Methods to Recruit Young Adults Who Use Prescription Opioids Nonmedically. Subst Use Misuse. 2018 Aug 24;53(10):1688–99.

**Tables**
Table 1
Schedule of enrolment and follow-up assessments of the RAPIDS Clinical Trial for the prevention of opioid overdose among people who use drugs.

| Activity                              | Timepoint (months) |
|---------------------------------------|--------------------|
|                                       | Screen | 0   | 1   | 2   | 3   | 6   | 12  |
|                                       |        | -t1 | 0   | 1   | 2   | 3   | 6   | 12  |
| **Enrolment**                         |        |     |     |     |     |     |     |
| Informed consent to screen           |        |     |     |     |     |     |     |
| Phone/email eligibility screen       |        |     |     |     |     |     |     |
| Informed consent to enrol            |        |     |     |     |     |     |     |
| Randomisation allocation              |        |     |     |     |     |     |     |
| **Intervention**                     |        |     |     |     |     |     |     |
| Motivational interview               |        | X   |     | X   | X   | X   |     |
| Role-play/teach-back                 |        | X   |     | X   | X   | X   |     |
| Training video                       |        | X   |     | X   | X   | X   |     |
| Usual care                           |        | X   |     | X   | X   | X   |     |
| **Assessment**                       |        |     |     |     |     |     |     |
| Self-report overdose                 |        |     |     |     |     |     | X   |
| Urine drug screening                 |        | X   |     | X   | X   | X   | X   |
| Sociodemographic characteristics     |        | X   |     | X   | X   | X   | X   |
| Substance use experiences            |        | X   |     | X   | X   | X   | X   |
| Overdose history                     |        | X   |     | X   | X   | X   | X   |
| Fentanyl exposure                    |        |     |     |     |     |     |     |
| Health care access                   |        | X   |     | X   | X   | X   | X   |
| Physical and mental health           |        | X   |     | X   | X   | X   | X   |
| Protocol deviation/Adverse event reporting |        | As needed throughout protocol |